Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder

References

• Kessler R C, McGonagle K A, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Archives of General Psychiatry 1994; 51: 8–19
   PubMed Web of Science ®Google Scholar
• Angst J, Selloro R. Historical perspectives and natural history of bipolar disorder. Biological Psychiatry 2000; 48: 445–457
   PubMed Web of Science ®Google Scholar
• Tohen M, Waternaux C M, Tsuang M T. Outcome in mania. Archives of General Psychiatry 1990; 47: 1106–1111
   PubMed Web of Science ®Google Scholar
• Tohen M, Tsuang M T, Goodwin D C. Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features. American Journal of Psychiatry 1992; 149: 1580–1584
   PubMed Web of Science ®Google Scholar
• Keck P E, Jr, McElroy S L, Strakowski S M, et al. 12-month outcome of patients with bipolar disorder following hospitalisation for a manic or mixed episode. American Journal of Psychiatry 1998; 155: 646–652
   PubMed Web of Science ®Google Scholar
• Goodwin F K, Jamison K R. Manic-depressive illness. Oxford University Press, New York 1990
   Google Scholar
• Harris E C, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. British Journal of Psychiatry 1997; 170: 205–228
   PubMed Web of Science ®Google Scholar
• Strakowski S M, Tohen M, Stoll A L, et al. Comorbidity in mania at first hospitalization. American Journal of Psychiatry 1992; 149: 554–556
   PubMed Web of Science ®Google Scholar
• Tohen M, Greenfield S F, Weiss R D, et al. The effect of comorbid substance use in disorders on the course of bipolar disorder: a review. Harvard Review in Psychiatry 1998; 6: 133–141
   PubMed Web of Science ®Google Scholar
• Coryell W, Scheftner W, Keller M, et al. The enduring psychosocial consequences of mania and depression. American Journal of Psychiatry 1993; 150: 720–727
   PubMed Web of Science ®Google Scholar
• Kessler R C, Rubinow D R, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychological Medicine 1997; 27: 1079–1089
   PubMed Web of Science ®Google Scholar
• Manji H K, Moore G J, Rajkowska G, et al. Neuroplasticity and cellular resilience in mood disorders. Molecular Psychiatry 2000; 5: 578–593
   PubMed Web of Science ®Google Scholar
• Sachs G S, Printz D J, Kahn D A, Carpenter D, Docherty J P. The expert consensus guideline series: Medication treatment of bipolar disorder 2000. McGraw-Hill, New York 2000; 1–104
   Google Scholar
• Bauer M S, Callahan A M, Jampala C, et al. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. Journal of Clinical Psychiatry 1999; 60: 9–21
   PubMed Web of Science ®Google Scholar
• Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of bipolar disorders. Part I. Treatment of bipolar depression. World Journal of Biological Psychiatry 2002; 3: 115–124
   PubMedGoogle Scholar
• Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of bipolar disorders. Part II. Treatment of mania. World Journal of Biological Psychiatry 2003; 4: 5–13
   PubMed Web of Science ®Google Scholar
• Therapeutic Guidelines. Therapeutic guidelines: Psychotropic. Therapeutic Guidelines, Melbourne 2003, Version 5
   Google Scholar
• Schou M. Forty years of lithium treatment. Archives of General Psychiatry 1997; 54: 9–13
   PubMed Web of Science ®Google Scholar
• Potter W Z, Ozcan M E. Methodological considerations for the development of new treatments for bipolar disorder. Australian and New Zealand Journal of Psychiatry 1998; 33: S84–S98
   Google Scholar
• Goodwin F K, Ghaemi S N. The impact of the discovery of lithium on psychiatric thought and practice in the USA and Europe. Australian and New Zealand Journal of Psychiatry 1999; 33: S54–S64
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. American Journal of Psychiatry 2002; 151: 1–36
   Google Scholar
• Wulsin L, Bachop M, Hoffman D. Group psychotherapy in manic-depressive illness. American Journal of Psychotherapy 1988; 42: 263–271
   PubMed Web of Science ®Google Scholar
• Lewis L. Consumer perspective concerning the diagnosis and treatment of bipolar disorder. Biological Psychiatry 2000; 48: 442–444
   PubMedGoogle Scholar
• McKeon P, O'Loughlin F. Bipolar disorder patients' attitudes to and knowledge of their illness: a retrospective study. Irish Journal of Psychological Medicine 1993; 10: 71–75
   Google Scholar
• Moncrieff J. Lithium revisited: a re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. British Journal of Psychiatry 1995; 167: 569–573
   PubMed Web of Science ®Google Scholar
• Cookson J. Lithium: balancing risks and benefits. British Journal of Psychiatry 1997; 171: 120–124
   PubMedGoogle Scholar
• Ballenger J C, Post R M. Carbamazepine in manic-depressive illness: a new treatment. American Journal of Psychiatry 1980; 137: 782–790
   PubMed Web of Science ®Google Scholar
• Goncalves N, Stoll K D. Carbamazepine in manic syndromes. A controlled double-blind study. Nervenarzt 1985; 56: 43–47
   PubMed Web of Science ®Google Scholar
• Post R M, Uhde T W, Roy-Byrne P P, et al. Correlates of antimanic response to carbamazepine. Psychiatry Research 1987; 21: 71–83
   PubMed Web of Science ®Google Scholar
• Klein E, Bental E, Lerer B, Belmaker R H. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. Archives of General Psychiatry 1984; 41: 165–170
   PubMed Web of Science ®Google Scholar
• Moller H J, Kissling W, Riehl T, et al. Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1989; 13: 127–136
   PubMed Web of Science ®Google Scholar
• Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. Journal of Clinical Psychiatry 1987; 48: 89–93
   PubMed Web of Science ®Google Scholar
• Small J G, Klapper M H, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Archives of General Psychiatry 1991; 48: 915–921
   PubMed Web of Science ®Google Scholar
• Pope H G, McElroy S L, Keck P E, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Archives of General Psychiatry 1991; 48: 62–68
   PubMed Web of Science ®Google Scholar
• Freeman T W, Clothier J L, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. American Journal of Psychiatry 1992; 149: 108–111
   PubMed Web of Science ®Google Scholar
• Bowden C L, Brugger A M, Swann A C, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. Journal of the American Medical Association 1994; 271: 918–924
   PubMed Web of Science ®Google Scholar
• Swann A C, Bowden C L, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Archives of General Psychiatry 1997; 54: 37–42
   PubMed Web of Science ®Google Scholar
• Mueller-Oerlinghausen B, Retzow A, Henn F A, et al. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicentre study. Journal of Clinical Psychopharmacology 2000; 20: 195–203
   PubMedGoogle Scholar
• McElroy S L, Keck P E, Stanton S P, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. Journal of Clinical Psychiatry 1996; 57: 142–146
   PubMed Web of Science ®Google Scholar
• Hirschfeld R MA, Allen M H, McEvoy J P, et al. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. Journal of Clinical Psychiatry 1999; 60: 815–818
   PubMedGoogle Scholar
• Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology 2000; 150: 15–23
   PubMed Web of Science ®Google Scholar
• Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Annals of Clinical Psychiatry 2000; 12: 5–10
   PubMedGoogle Scholar
• Frye M A, Ketter T A, Kimbrell T A, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology 2000; 20: 607–614
   PubMed Web of Science ®Google Scholar
• Pande A C, Crockatt J G, Janney C A, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disorders 2000; 2: 249–255
   PubMed Web of Science ®Google Scholar
• Calabrese J R, Kimmell S E, Woyshville M J, et al. Clozapine for treatment of refractory mania. American Journal of Psychiatry 1996; 153: 759–764
   PubMed Web of Science ®Google Scholar
• Tohen M, Sanger T M, McElroy S L, et al. The Olanzapine HGEH Study Group. Olanzapine versus placebo in the treatment of acute mania. American Journal of Psychiatry 1999; 156: 702–709
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs T G, Grundy S L, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Archives of General Psychiatry 2000; 57: 841–849
   PubMed Web of Science ®Google Scholar
• Tohen M, Baker R W, Altshuler L L, et al. Olanzapine versus divalproex in the treatment of acute mania. American Journal of Psychiatry 2002; 159: 1011–1017
   PubMed Web of Science ®Google Scholar
• Zajecka J M, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. Journal of Clinical Psychiatry 2002; 63: 1148–1155
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa R, Suppes T, et al. Efficacy of olanzapine in combination with valproate in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Archives of General Psychiatry 2002; 59: 62–69
   PubMed Web of Science ®Google Scholar
• Tohen M, Goldberg J F, Gonzalez-Pinto Arrillaga A M, et al. A 12–week, double–blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Archives of General Psychiatry 2003; 60: 1218–1226
   PubMed Web of Science ®Google Scholar
• Sachs G S, Grossman F, Ghaemi S N, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. American Journal of Psychiatry 2002; 159: 1146–1154
   PubMed Web of Science ®Google Scholar
• Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clinical Neuropharmacology 1998; 21: 176–180
   PubMed Web of Science ®Google Scholar
• Small J G, Klapper M H, Kellams J J, et al. ECT compared with lithium in the management of manic states. Archives of General Psychiatry 1988; 45: 727–732
   PubMed Web of Science ®Google Scholar
• Markowitz G S, Radhakrishnan J, Kambham N, et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointersitial nephropathy. Journal of the American Society of Nephrology 2000; 11: 1439–1448
   PubMed Web of Science ®Google Scholar
• Rasgon N L, Altshuler L L, Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. Journal of Clinical Psychiatry 2000; 61: 173–178
   PubMedGoogle Scholar
• Kilts C D. The ups and downs of oral lithium dosing. Journal of Clinical Psychiatry 1988; 59: 21–26
   Google Scholar
• Amdisen A. Serum lithium determinations for clinical use. Scandinavian Journal of Clinical and Laboratory Investigation 1967; 20: 104–108
   Web of Science ®Google Scholar
• Amdisen A. Clinical features and management of lithium poisoning. Medical Toxicology 1988; 3: 18–32
   Google Scholar
• Amdisen A. Clinical and serum-level monitoring in lithium therapy and lithium intoxication. Journal of Analytical Toxicology 1978; 2: 193–202
   Web of Science ®Google Scholar
• American Psychiatric Association. American Psychiatric Association practice guidelines. American Psychiatric Press, Washington, DC 1996
   Google Scholar
• Schou M. Lithium prophylaxis: myths and realities. American Journal of Psychiatry 1989; 146: 573–576
   PubMed Web of Science ®Google Scholar
• Gelenberg A J, Carroll J A, Baudhuin M LS, et al. The meaning of serum lithium levels in maintenance therapy of mood disorders: a review of the literature. Journal of Clinical Psychiatry 1989; 50: 45–47
   Google Scholar
• Stokes P E, Kocsis J H, Arcuni O J. Relationship of lithium chloride dose to treatment response in acute mania. Archives of General Psychiatry 1976; 33: 1080–1084
   PubMed Web of Science ®Google Scholar
• Waters B, Lapierre Y D, Gagnon A, et al. Determination of the optimal concentration of lithium for the prophylaxis of manic depressive disorder. Biological Psychiatry 1982; 17: 1323–1329
   PubMed Web of Science ®Google Scholar
• Gelenberg A J, Kane J M, Keller M B, et al. Comparison of standard low serum levels for lithium for maintenance treatment of bipolar disorder. New England Journal of Medicine 1989; 321: 1489–1493
   PubMed Web of Science ®Google Scholar
• Keller M B, Lavori P W, Kane J M, et al. Subsyndromal symptoms in bipolar disorder. Archives of General Psychiatry 1992; 49: 371–376
   PubMedGoogle Scholar
• Solomon D A, Ristow W R, Keller M B, et al. Serum lithium levels and psychosocial function in patients with bipolar I disorder. American Journal of Psychiatry 1996; 153: 1301–1307
   PubMed Web of Science ®Google Scholar
• Jerrum T C, McDonald R. Plasma lithium control with particular reference to minimum effective levels. Lithium in medical practice, F N Johnson, S Johnson. MTP Press, Lancaster 1978; 407–413
   Google Scholar
• Coppen A, Abou-Saleh M, Milln P, et al. Decreasing lithium dosage reduces morbidity and side-effects during prophylaxis. Journal of Affective Disorders 1983; 5: 353–362
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Licht R W, Brodersen A, et al. Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. Acta Psychiatrica Scandinavica 1998; 98: 310–315
   PubMed Web of Science ®Google Scholar
• Speirs J, Hirsch S R. Severe lithium toxicity with ‘normal’ serum concentrations. British Medical Journal 1978; 1: 815–816
   PubMedGoogle Scholar
• Gadallah M F, Feinstein E I, Massry S G. Lithium intoxication: clinical course and therapeutic concentrations. Mineral Electrolyte Metabolism 1988; 14: 146–149
   PubMedGoogle Scholar
• Finley P R, Warner M D, Peabody C A. Clinical relevance of during interactions with lithium. Clinical Pharmacokinetics 1995; 29: 172–191
   PubMed Web of Science ®Google Scholar
• Shirley D G, Walter S J, Thomsen K. A comparison of micropuncture and lithium clearance methods in the assessment of renal tubular function in rats with diabetes insipidus. Pfugers Archives 1983; 399: 266–270
   PubMed Web of Science ®Google Scholar
• Eadie M J. Therapeutic drug monitoring: anti-epileptic drugs. British Journal of Clinical Pharmacology 1998; 46: 183–193
   Google Scholar
• Kilpatrick C J, Fullinfaw R O, Bury R W, et al. Plasma concentrations of unbound valproate and the management of epilepsy. Australian and New Zealand Journal of Psychiatry 1987; 17: 574–579
   Google Scholar
• Bowden C L, Janicak P G, Orsulak P, et al. Relation to serum valproate concentration to response in mania. American Journal of Psychiatry 1996; 153: 765–770
   PubMed Web of Science ®Google Scholar
• Post R M, Uhde T W, Ballenger J C, et al. Carbamazepine and its –10,11-epoxide metabolite in plasma and CSF. Archives of General Psychiatry 1983; 40: 673–676
   PubMed Web of Science ®Google Scholar
• Simhandl C, Denk E, Thau K. The comparative efficacy of carbamazapine low and high serum level and lithium carbonate in the prophylaxis of affective disorder. Journal of Affective Disorders 1993; 28: 221–231
   PubMed Web of Science ®Google Scholar
• Emilien G, Maloteux J M, Seghers A, et al. Lithium compared to valproic acid and carbamazapine in the treatment of mania: a statistical meta-analysis. European Neuropsychopharmacology 1996; 6: 245–252
   PubMed Web of Science ®Google Scholar
• Poolsup N, Li Wan Po A, de Oliveira I R. Systematic overview of lithium treatment in acute mania. Journal of Clinical Pharmacy and Therapeutics 2000; 25: 139–156
   PubMed Web of Science ®Google Scholar
• Fieve R R, Platman S R, Plutchik R R. The use of lithium in affective disorders. I. acute endogenous depression. American Journal of Psychiatry 1968; 125: 79–83
   Google Scholar
• Goodwin F K, Murphy D L, Bunney W E. Lithium carbonate treatment in depression and mania. Archives of General Psychiatry 1969; 21: 486–496
   PubMed Web of Science ®Google Scholar
• Greenspan K, Schildkraut J J, Gordon E K, et al. Catecholamine metabolism in affective disorders. III. Journal of Psychiatric Research 1970; 7: 171–182
   PubMed Web of Science ®Google Scholar
• Stokes P E, Stoll P M, Shamoian C A, et al. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971; 1: 1319–1325
   PubMed Web of Science ®Google Scholar
• Goodwin F K, Murphy D L, Dunner D L, et al. Lithium response in unipolar versus bipolar depression. American Journal of Psychiatry 1972; 129: 76–79
   Google Scholar
• Noyes R, Dempsey G M, Blum A, et al. Lithium treatment of depression. Comprehensive Psychiatry 1974; 15: 187–193
   PubMed Web of Science ®Google Scholar
• Mendels J. Lithium in the treatment of depression. American Journal of Psychiatry 1976; 4: 373–378
   Google Scholar
• Baron M, Gershon E S, Rudy V, et al. Lithium carbonate response in depression. Archives of General Psychiatry 1975; 32: 1107–1111
   PubMed Web of Science ®Google Scholar
• Donnelly E F, Goodwin F K, Waldman I N, et al. Prediction of antidepressant response to lithium. American Journal of Psychiatry 1978; 135: 552–556
   PubMed Web of Science ®Google Scholar
• Zornberg G L, Pope H G, Jr. Treatment of depression in bipolar disorder: new directions for research. Journal of Clinical Psychopharmacology 1993; 13: 397–408
   PubMed Web of Science ®Google Scholar
• Suppes T, Baldessarini R J, Faedda G L, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Archives of General Psychiatry 1991; 48: 1082–1088
   PubMed Web of Science ®Google Scholar
• Heit F, Nemeroff C B. Lithium augmentation of antidepressants in treatment-refractory depression. Journal of Clinical Psychiatry 1998; 59: 28–33
   PubMed Web of Science ®Google Scholar
• Franchini L, Zanardi R, Gasperini M, et al. Fluvoxamine and lithium in long-term of unipolar subjects with high reccurence rate. Journal of Affective Disorders 1996; 38: 67–69
   PubMedGoogle Scholar
• Ballenger J C, Post R M. Carbamazapine in manic-depressive illness: a new treatment. American Journal of Psychiatry 1980; 137: 782–790
   PubMed Web of Science ®Google Scholar
• Post R M, Uhde T W, Roy-Byrne P, et al. Antidepressant effects of carbamazepine. American Journal of Psychiatry 1986; 143: 29–34
   PubMed Web of Science ®Google Scholar
• Post R M, Leverich G S, Denicoff K D, et al. Alternative approaches to refractory depression in bipolar illness. Depression and Anxiety 1997; 5: 73–83
   PubMedGoogle Scholar
• Dilsaver S C, Swann S C, Chen Y, et al. Treatment of bipolar depression with carbamazepine: Results of an open study. Biological Psychiatry 1996; 40: 935–937
   PubMedGoogle Scholar
• Kramlinger K G, Post R M. The addition of lithium to carbamazepine. Archives of General Psychiatry 1989; 46: 794–800
   PubMedGoogle Scholar
• Post R M, Ketter T A, Denicoff K, et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology 1996; 128: 115–129
   PubMed Web of Science ®Google Scholar
• Young L T, Joffe R T, Robb J C, et al. Double-blind comparison of addition of a second mood stabiliser versus an antidepressant to an initial mood stabiliser for treatment of patients with bipolar depression. American Journal of Psychiatry 2000; 157: 124–126
   PubMed Web of Science ®Google Scholar
• McElroy S L, Keck P E, Jr. Treatment guidelines for valproate in bipolar, schizoaffective disorders. Canadian Journal of Psychiatry 1993; 38: 62–66
   PubMedGoogle Scholar
• Winsberg M E, DeGolia S G, Strong C M, et al. Divalproex therapy in medication-naïve and mood-stabiliser-naïve bipolar II depression. Journal of Affective Disorders 2001; 67: 207–212
   PubMed Web of Science ®Google Scholar
• Bowden C L, Calabrese J R, McElroy S L, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Archives of General Psychiatry 2000; 57: 481–489
   PubMed Web of Science ®Google Scholar
• Calabrese J R, Bowden C L, Sachs G S, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar 1 depression. Journal of Clinical Psychiatry 1999; 60: 79–88
   PubMed Web of Science ®Google Scholar
• Bowden C L. Novel treatments for bipolar disorder. Expert Opinion on Investigational Drugs 2001; 10: 661–915
   PubMed Web of Science ®Google Scholar
• Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. British Journal of Psychiatry 1994; 164: 549–550
   PubMed Web of Science ®Google Scholar
• Cohn J B, Collins G, Ashbrook E, et al. A comparison of flouxetine, imipramine and placebo in patients with bipolar depressive disorder. International Clinical Psychopharmacology 1989; 4: 313–322
   PubMed Web of Science ®Google Scholar
• Sachs G S, Lafer B, Stoll A L, et al. A double blind trial of bupropion versus desipramine for bipolar depression. American Journal of Psychiatry 1994; 55: 910–919
   Google Scholar
• Wehr T A, Goodwin F K. Can antidepressants cause mania and worsen the course of affective illness? American Journal of Psychiatry. 1987; 144: 1403–1411
   Google Scholar
• Frye M A, Denicoff K D, Bryan A L, et al. Association between low serum free T4 and greater mood instability and depression in lithium maintained bipolar patients. American Journal of Psychiatry 1999; 156: 1909–1914
   PubMedGoogle Scholar
• Dilsaver S C, Swann A C. Mixed mania: apparent induction by a tricyclic antidepressants in five consecutively treated patients with bipolar disorder. Biological Psychiatry 1995; 37: 60–62
   PubMed Web of Science ®Google Scholar
• Boerlin H L, Gitlin M J, Zoellner L A, et al. Bipolar depression and antidepressant-induced mania: a naturalistic study. Journal of Clinical Psychiatry 1998; 59: 374–381
   PubMed Web of Science ®Google Scholar
• Bottlender R, Rudolf D, Straub A. Mood-stabilizers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar 1 depressed patients. Journal of Affective Disorders 2001; 63: 79–83
   PubMed Web of Science ®Google Scholar
• Lewis J L, Winokur G. The induction of mania: a natural history study with controls. Archives of General Psychiatry 1982; 39: 303–306
   PubMed Web of Science ®Google Scholar
• Rouillon F, Lejoyeaux M, Filteau M J. Unwanted effects of longterm treatment. Longterm treatment of depression, S A Montgomery, F A Rouillon. Wiley, New York 1992
   Google Scholar
• Silverstone T. A double-blind multicentre trial of moclobemide vs. Imipramine in bipolar depression. European Neuropsychopharmacology 1997; 7: 169–170
   Google Scholar
• Nemeroff C B, Evans D L, Gyulai L, et al. Double -blind, placebo controlled comparison of imipramine and paroxitine in the treatment of bipolar depression. American Journal of Psychiatry 2001; 158: 906–912
   PubMed Web of Science ®Google Scholar
• Himmelhoch J M, Thase M E, Mallinger A G, et al. Tranylcypromine versus imipramine in anergic bipolar depression. American Journal of Psychiatry 1991; 148: 910–916
   PubMed Web of Science ®Google Scholar
• Baumhackl U, Biziere K, Fischbach R, et al. Efficacy and tolerability of moclobemide compared with imipramine in depressive disorders. British Journal of Psychiatry 1989; 155: 78–83
   Google Scholar
• Robertson M M, Trimble M R. Neuroleptics as antidepressants. Neuropharmacology 1981; 20: 1335–1336
   PubMed Web of Science ®Google Scholar
• Spiker D G, Weiss J C, Dealy R S, et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry 1985; 142: 430–436
   PubMed Web of Science ®Google Scholar
• Parker G, Malhi G. Are atypical antipsychotics drugs also atypical antidepressants?. Australian and New Zealand Journal of Psychiatry 2001; 35: 631–638
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine/fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 2003; 60: 1079–1088
   PubMed Web of Science ®Google Scholar
• Ghaemi S N. On defining ‘mood stabilizer’. Bipolar Disorders 2001; 3: 154–158
   PubMed Web of Science ®Google Scholar
• Shelton R C. Mood-stabilizing drugs in depression. Journal of Clinical Psychiatry 1999; 60: 37–40
   PubMed Web of Science ®Google Scholar
• Suppes T, Webb A, Paul B, et al. Clinical outcomes in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. American Journal of Psychiatry 1999; 156: 1164–1166
   PubMed Web of Science ®Google Scholar
• Malhi G S, Mitchell P B, Caterson I. Why getting fat, Doc? Weight gain and psychotropic medications. Australian and New Zealand Journal of Psychiatry 2001; 35: 315–321
   PubMed Web of Science ®Google Scholar
• Daly J J, Prudic J, Devanand D P, et al. ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disorders 2001; 3: 95–104
   PubMed Web of Science ®Google Scholar
• Prudic J, Sackeim H, Devanand D P. Medication resistance and clinical response to ECT. Psychiatry Research 1990; 31: 287–296
   PubMed Web of Science ®Google Scholar
• NIMH/NIH Consensus Development Panel. NIMH/NIH Consensus Development Conference statement. Mood disorders. pharmacologic prevention of recurrences. Consensus Development Panel. American Journal of Psychiatry 1985; 142: 469–476
   PubMedGoogle Scholar
• Grof P, Angst J, Karasek M, et al. Patient selection for long-term lithium treatment in clinical practice. Archives of General Psychiatry 1979; 36: 894–897
   PubMedGoogle Scholar
• Prien R F, Gelenberg A J. Alternatives to lithium for preventive treatment of bipolar disorder. American Journal of Psychiatry 1989; 146: 840–848
   PubMedGoogle Scholar
• Jamison K R, Gerner R H, Goodwin F K. Patient and physician attitudes toward lithium: relationship to compliance. Archives of General Psychiatry 1979; 36: 866–869
   PubMed Web of Science ®Google Scholar
• Okuma T, Inanaga K, Otsuki S, et al. A preliminary double-blind study on the efficacy of carbamazapine in prophylaxis of manic-depressive illness. Psychopharmacology 1981; 73: 95–95
   PubMed Web of Science ®Google Scholar
• Lusznat R M, Murphy D P, Nunn C MH. Carbamazepine vs lithium in the treatment and prophylaxis of mania. British Journal of Psychiatry 1988; 153: 198–204
   PubMed Web of Science ®Google Scholar
• Watkins S E, Callender K, Thomas D R, et al. The effect of carbamazepine and lithium on remission from affective illness. British Journal of Psychiatry 1987; 150: 180–182
   PubMed Web of Science ®Google Scholar
• Placidi G F, Lenzi A, Lazzerini F, et al. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. Journal of Clinical Psychiatry 1986; 47: 490–494
   PubMed Web of Science ®Google Scholar
• Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatrica Scandinavica 1992; 85: 114–118
   PubMed Web of Science ®Google Scholar
• Denicoff K D, Smith-Jackson E E, Disney E R, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. Journal of Clinical Psychiatry 1997; 58: 470–478
   PubMed Web of Science ®Google Scholar
• Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium vs. carbamazepine in the maintenance treatment of bipolar disorders–a randomized study. Journal of Affective Disorders 1997; 43: 151–161
   PubMed Web of Science ®Google Scholar
• Lambert P A, Venaud G. Comparative study of valpromide versus lithium as prophylactic treatment in affective disorders. Nervure Journal of Psychiatrie 1992; 7: 1–9
   Google Scholar
• Calabrese J R, Rapport D J, Kimmel S E, et al. Rapid cycling bipolar disorder and its treatment with valproate. Canadian Journal of Psychiatry 1993; 38: 57–60
   Web of Science ®Google Scholar
• Bowden C L, Calabrese J R, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry 2003; 60: 392–400
   PubMed Web of Science ®Google Scholar
• Calabrese J R, Bowden C L, Sachs G, et al. A placebo–controlled 18–month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar disorder. Journal of Clinical Psychiatry 2003; 64: 1013–1024
   PubMed Web of Science ®Google Scholar
• Kramlinger K G, Post R M. Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment-resistant mania. Acta Psychiatrica Scandinavica 1989; 79: 378–385
   PubMedGoogle Scholar
• Denicoff K D, Smith-Jackson E E, Bryan A L, et al. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. American Journal of Psychiatry 1997; 154: 1456–1458
   PubMedGoogle Scholar
• Baldessarini R J, et al. Effects of lithium treatment and its discontinuation on suicidal behaviour in bipolar manic depressive disorders. Journal of Clinical Psychiatry 1999; 60: 77–84
   PubMed Web of Science ®Google Scholar
• Scott J. Psychotherapy for bipolar disorder. British Journal of Psychiatry 1995; 167: 581–588
   PubMed Web of Science ®Google Scholar
• Kahn D A. The use of psychodynamic psychotherapy in manic-depressive illness. Journal of the American Academy of Psychoanalysis 1993; 21: 441–455
   PubMedGoogle Scholar
• Seltzer A, Roncari I, Garfinkel P. Effect of patient education on medication compliance. Canadian Journal of Psychiatry 1980; 16: 638–645
   Google Scholar
• Peet M, Harvey N S. Lithium maintenance: 1: a standard education programme for patients. British Journal of Psychiatry 1991; 158: 197–200
   PubMed Web of Science ®Google Scholar
• Van Gent E M, Zwart F M. Psychoeducation of partners of bipolar-manic patients. Journal of Affective Disorders 1991; 21: 15–18
   PubMed Web of Science ®Google Scholar
• Cochran S D. Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. Journal of Consulting Clinical Psychiatry 1984; 52: 873–878
   PubMed Web of Science ®Google Scholar
• Perry A, Tarrier N, Morriss R, McCarthy E, et al. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. British Medical Journal 1999; 318: 149–153
   PubMed Web of Science ®Google Scholar
• Alloy L B, Abramson L Y, Whitehouse W G, et al. Depressogenic cognitive styles: predictive validity, information processing and personality characteristics and developmental origins. Behaviour Research and Therapy 1999; 37: 503–531
   PubMed Web of Science ®Google Scholar
• Haaga D A, Dyck M J, Ernst D. Empirical status of cognitive therapy of depression. Psychological Bulletin 1991; 110: 215–236
   PubMed Web of Science ®Google Scholar
• Reilly-Harrington N A, Alloy L B, Fresco D M, et al. Cognitive styles and life events interact to predict bipolar and unipolar symptomatology. Journal of Abnormal Psychology 1999; 108: 567–578
   PubMed Web of Science ®Google Scholar
• Scott J. Cognitive therapy as an adjunct to medication in bipolar disorder. British Journal of Psychiatry 2001; 178: s164–s168
   PubMed Web of Science ®Google Scholar
• Basco M R, Rush A J. Compliance with pharmacotherapy in mood disorders. Psychiatric Annals 1995; 25: 78–82
   Google Scholar
• Patelis-Siotis I, Young L T, Robb J C, et al. Group cognitive behavioural therapy for bipolar disorder: a feasibility and effectiveness study. Journal of Affective Disorders 2001; 65: 145–153
   PubMed Web of Science ®Google Scholar
• Chor P H, Mercler M, Halper I. Use of cognitive therapy for patients suffering from bipolar affective disorder. Journal of Cognitive Psychotherapy: an International Quarterly 1988; 2: 51–58
   Google Scholar
• Beck A T, Rush A J, Shaw B F, et al. Cognitive therapy of depression. Pergamon, Elmsford, NY 1979
   Google Scholar
• Palmer A G, Williams H, Adams M. Cognitive behavior therapy for bipolar affective disorder in a group format. Behavioural Cognitive Psychotherapy 1995; 23: 153–168
   Google Scholar
• Palmer A G, Williams H, Adams M. CBT in a group format for bipolar affective disorder. Behavioural and Cognitive Psychotherapy 1995; 23: 153–168
   Google Scholar
• Bauer M, McBride L, Chase C, et al. Manual based group psychotherapy for bipolar disorder: a feasibility study. Journal of Clinical Psychiatry 1998; 59: 449–455
   PubMed Web of Science ®Google Scholar
• Zaretsky A E, Segal Z V, Gemar M. Cognitive therapy for bipolar depression: a pilot study. Canadian Journal of Psychiatry 1999; 44: 491–494
   PubMed Web of Science ®Google Scholar
• Lam D H, Bright J, Jones S, et al. Cognitive therapy for bipolar illness: a pilot study of relapse prevention. Cognitive Therapy Research 2000; 24: 303–320
   Google Scholar
• Lam D H, Watkins E R, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Archives of General Psychiatry 2003; 60: 145–152
   PubMed Web of Science ®Google Scholar
• Hirschfeld D R, Gould R A, Reilly-Harrington N A, et al. Short-term adjunctive cognitive-behavioural group therapy for bipolar disorder: preliminary results from a controlled trial. Paper Presented at the Annual Meeting of the Association for the Advancement of Behaviour Therapy Conference. Association for the Advancement of Behaviour Therapy, Washington, DC 1998
   Google Scholar
• Newman C F, Leahy R L, Beck A T, et al. Bipolar disorder: a cognitive therapy approach. American Psychological Association, Washington, DC 2002
   Google Scholar
• Ball J, Mitchell P, Malhi G, et al. Schema-focused cognitive therapy for bipolar disorder: reducing vulnerability to relapse through attitudinal change. Australian and New Zealand Journal of Psychiatry 2003; 37: 41–48
   PubMed Web of Science ®Google Scholar
• Young J E. Cognitive therapy for personality disorders: a schema-focused approach. Professional Resource Press, Sarasota, FL 1990
   Google Scholar
• Young J, Behary W T. Schema-focused therapy for personality disorders. Treating complex cases: the cognitive behavioural therapy approach, N Tarrier, A Wells, G Haddock. Wiley, Chichester 1998; 340–376
   Google Scholar
• Cooper M. Cognitive behaviour therapy in an inpatient with chronic difficulties: a case report. Behaviour Research and Therapy 1994; 22: 171–176
   Google Scholar
• Morrison N. Schema-focused cognitive therapy for complex long-standing problems: a single case study. Behavioural Cognitive Psychotherapy 2000; 28: 269–283
   Google Scholar
• Frank E, Kupfer D J, Ehlers C L, et al. Interpersonal and social rhythm therapy for bipolar disorder: Integrating interpersonal and behavioural approaches. Behaviour Therapy 1994; 17: 153–166
   Google Scholar
• Klerman G L. Principles of interpersonal psychotherapy for depression;. Depression and mania, A Georgotas, R Cancro. Elsevier, New York 1988
   Google Scholar
• Davenport Y B, Ebert M H, Adland M L, et al. Couples group therapy as an adjunct to lithium maintenance of the manic patient. American Journal of Orthopsychiatry 1977; 47: 495–502
   PubMed Web of Science ®Google Scholar
• Shakir S A, Volkmar F R, Bacon S. Group psychotherapy as an adjunct to lithium maintenance. American Journal of Psychiatry 1979; 136: 455–456
   PubMed Web of Science ®Google Scholar
• Kripke D F, Robinson D. Ten years with a lithium group. McLean Hospital Journal 1985; 10: 1–11
   Google Scholar
• Bauer M, McBride R. Structured group psychotherapy for bipolar disorder. The Life Goals Program. Springer, New York 1997
   Google Scholar
• Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Archives of General Psychiatry 2003; 60: 402–407
   PubMed Web of Science ®Google Scholar
• Craighead W E, Miklowitz D J. Psychosocial interventions for bipolar disorder. Journal of Clinical Psychiatry 2000; 13(Suppl.)58–64
   Google Scholar
• Simomeau T L, Miklowitz D J, Saleem R. Expressed emotion and interactional patterns in the families of bipolar patients. Journal of Abnormal Psychology 1998; 107: 497–507
   PubMedGoogle Scholar
• Clarkin J F, Glick I D, Haas G L, et al. A randomized clinical trial of inpatient family intervention: C. results for affective disorders. Journal of Affective Disorders 1990; 18: 17–28
   PubMed Web of Science ®Google Scholar
• Clarkin J F, Carpenter D, Hull J, et al. Effects of psychoeducational intervention for married patients with bipolar disorder and their spouses. Psychiatric Services 1998; 49: 531–533
   PubMed Web of Science ®Google Scholar
• Miklowitz D J, Simoneau T L, George E L, et al. Family focused treatment of bipolar disorder: 1-year effects in a psychoeducational program in conjunction with pharmacotherapy. Biological Psychiatry 2000; 48: 582–592
   PubMed Web of Science ®Google Scholar
• Goldstein M J, Rea M M, Miklowitz D J. Family factors related to the course and outcome of bipolar disorder. Interpersonal factors in the origin, course of affective disorders, C Mundt, M J Goldstein, K Hahlweg, et al. Gaskell, London 1996; 193–203
   Google Scholar
• Miller I W, Keitner G I, Bishop D S, et al. Families of bipolar patients: dysfunction, course of illness and pilot treatment study. Paper presented at the meetings of the Association of Behaviour Therapy. Association of Behaviour Therapy, New York 1991
   Google Scholar
• Miller I W, Keitner G I, Ryan C E, et al. Family treatment of bipolar disorder. Paper presented at the meetings of the Society for Psychotherapy Research. Society for Psychotherapy Research, BraagaPortugal 2000
   Google Scholar
• Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders (Cochrane Review). The Cochrane Library 4. Update Software, Oxford 2001
   Google Scholar
• Prien R F, Klett C J, Caffey E M, Jr. Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness. Archives of General Psychiatry 1973; 29: 420–425
   PubMed Web of Science ®Google Scholar
• Kane J M, Quitkin F M, Rifkin A, et al. A. Lithium carbonate and Imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Archives of General Psychiatry 1982; 39: 1065–1069
   PubMed Web of Science ®Google Scholar
• Macritchie K AN, Geddes J R, Scott J, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Cochrane Review). The Cochrane Library 4. Update Software, Oxford 2001
   Google Scholar
• Dardennes R, Even C, Bange F, et al. Comparison of carbamazapine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. British Journal of Psychiatry 1995; 166: 378–381
   PubMed Web of Science ®Google Scholar
• Davis J M, Janicak P G, Hogan D M. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatrica Scandinavica 1999; 100: 406–417
   PubMed Web of Science ®Google Scholar
• Frances A J, Kahn D A, Carpenter D, et al. The expert consensus guidelines for treating depression in bipolar disorder. Journal of Clinical Psychiatry 1998; 59: 73–79
   PubMed Web of Science ®Google Scholar
• Calabrese J R, Delucchi G A. Phenomenology of rapid cycling manic depression and its treatment with valproate. Journal of Clinical Psychiatry 1989; 50: 30–34
   PubMedGoogle Scholar
• Harvey A T, Rudolph R L, Preskorn S H. Evidence of the dual mechanisms of action of venlafaxine. Archives of General Psychiatry 2000; 57: 503–309
   PubMed Web of Science ®Google Scholar
• Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar 2 major depressive episode. Journal of Clinical Psychopharmacology 1998; 18: 414–417
   PubMed Web of Science ®Google Scholar
• Thase M E, Sachs G S. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biological Psychiatry 2000; 48: 558–572
   PubMed Web of Science ®Google Scholar
• Quitkin F M, Kane J, Rifkin A, et al. Prophylactic lithium carbonate with or without Imipramine for bipolar I patients. Archives of General Psychiatry 1981; 38: 902–907
   PubMed Web of Science ®Google Scholar
• Prien R F, Kupfer D J, Mansky P A, et al. During therapy in prevention of recurrences in unipolar and bipolar affective disorders: report of NIMH Collaborative Study Group comparing lithium carbonate, imipramine and lithium carbonate-imipramine combination. Archives of General Psychiatry 1984; 41: 1096–1104
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Yatham L N, Zis A. Treatment of acute bipolar depression: a review of the literature. Canadian Journal of Psychiatry 1995; 40: 533–544
   PubMedGoogle Scholar
• Himmelhoch J M, Fuchs C Z, Symons B J. A double-blind study of tranylcypromine treatment of major anergic depression. Journal of Nervous and Mental Disease 1982; 170: 628–634
   PubMedGoogle Scholar
• Sackeim G A, Rush A J. Melancholia and response to ECT. American Journal of Psychiatry 1995; 152: 1242–1243
   PubMedGoogle Scholar
• Bauer M S, Whybrow P C. Rapid cycling bipolar affective disorder. II. treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Archives of General Psychiatry 1990; 47: 435–440
   PubMed Web of Science ®Google Scholar
• Schou M. Lithium treatment during pregnancy, delivery and lactation: an update. Journal of Clinical Psychiatry 1990; 51: 410–413
   PubMed Web of Science ®Google Scholar
• Cohen L S, Friedman J M, Jefferson J W, et al. A reevaluation of risk of utero exposure to lithium. Journal of the American Medical Association 1994; 271: 146–150
   PubMedGoogle Scholar
• Jacobson S J, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339: 530–533
   PubMed Web of Science ®Google Scholar
• Schou M, Amdisen A. Lithium and the placenta (letter). American Journal of Obstetrics and Gynecology 1995; 122: 541
   Google Scholar
• Schou M. What happened to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatrica Scandinavica 1976; 54: 193–197
   PubMed Web of Science ®Google Scholar
• Koren G, Pastuszak A, Jacobson S, . The safety of antidepressants in pregnancy. Maternal and fetal toxicology a clinician guide, G Koren, et al. Dekker, New York 1994; 59–76
   Google Scholar
• Rosa F. Spina bifida in infants of women treated with carbamazapine during pregnancy. New England Journal of Medicine 1991; 324: 674–677
   PubMed Web of Science ®Google Scholar
• Omtzigt J GC, Los F J, Grobbee D E, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992; 42: 119–125
   PubMed Web of Science ®Google Scholar
• Thisted E, Ebbesen F. Malformations, withdrawal manifestations and hypoglycemia after exposure to valproate in utero. Archives of Disabilities in Childhood 1993; 69: 288–291
   PubMed Web of Science ®Google Scholar
• Altshuler L L, Cohen L, Szuba M P, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. American Journal of Psychiatry 1996; 153: 592–606
   PubMed Web of Science ®Google Scholar
• McNeil T F. A prospective study of postpartum psychosis in a high risk group: relationship to demographic and psychiatric history characteristics. Acta Psychiatrica Scandinavica 1987; 73: 35–43
   Google Scholar
• Reich T, Winokur G. Postpartum psychoses in patients with manic depressive disease. Journal of Nervous and Mental Disease 1970; 151: 60–68
   PubMed Web of Science ®Google Scholar
• Piontek C M, Baab S, Peindl K S, et al. Serum valproate levels in six breastfeeding mother-infant pairs. Journal of Clinical Psychiatry 2000; 61: 170–172
   PubMed Web of Science ®Google Scholar
• Yoshida K, Kumar R. Breast feeding and psychotropic drugs. International Review of Psychiatry 1996; 8: 117–124
   Web of Science ®Google Scholar
• Chisholm C A, Kuller J A. A guide to the safety of CNS-active agents during breastfeeding. Drug Safety 1997; 17: 127–142
   PubMed Web of Science ®Google Scholar
• Fisher M. Guide to clinical preventive services: an assessment of the effectiveness of 169 interventions, M Fisher. Williams and Williams, Baltimore 1989; 388
   Google Scholar